Comparison of individual antigen specificities and sensitivities.

Data shown for 96 cancers (% sensitivity), 96 matched normal sera (% specificity) and at risk sera (% positivity). Study 1: Data from initial screen of 41 antigens. Study 2: Data from the 21 lead antigens. Individual cut-offs for each antigen were applied to maximise cancer: normal differentiation.TAA – tumor-associated antigens. n/a – not assessed.Rejected antigens = Vitronectin; Survivin; KOC; p62; α-enolase; c-myc; GBU4-5, β-Catenin 1; CAGE; HuD; H-RAS-2; PRDX6; IMP1; K-RAS; MAGE-A4; MAGE-C2; SOX2; SSX1; VEGF-C; WT1-c-terminal.